LRRC19
Leucine-rich repeat-containing protein 19
Also known as: FLJ21302, LRC19_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H756
- Gene
- LRRC19
- Ensembl
- ENSG00000184434
- Chromosome
- 9
- Canonical length
- 370 aa
- Protein class
- Predicted membrane proteins
OverviewNCBI Gene
Predicted to enable signaling receptor activity. Acts upstream of or within positive regulation of non-canonical NF-kappaB signal transduction. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
370 residues, UniProt reviewed canonical sequence.
>Q9H756|LRRC19
1 MKVTGITILF WPLSMILLSD KIQSSKREVQ CNFTEKNYTL IPADIKKDVT ILDLSYNQIT
61 LNGTDTRVLQ TYFLLTELYL IENKVTILHN NGFGNLSSLE ILNICRNSIY VIQQGAFLGL
121 NKLKQLYLCQ NKIEQLNADV FVPLRSLKLL NLQGNLISYL DVPPLFHLEL ITLYGNLWNC
181 SCSLFNLQNW LNTSNVTLEN ENITMCSYPN SLQSYNIKTV PHKAECHSKF PSSVTEDLYI
241 HFQPISNSIF NSSSNNLTRN SEHEPLGKSW AFLVGVVVTV LTTSLLIFIA IKCPIWYNIL
301 LSYNHHRLEE HEAETYEDGF TGNPSSLSQI PETNSEETTV IFEQLHSFVV DDDGFIEDKY
361 IDIHELCEENLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LRRC19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 40 nTPM
Expression across tissuesHPA
Tissue
- kidney: 40 nTPM
- colon: 34 nTPM
- rectum: 31 nTPM
- small intestine: 30 nTPM
- duodenum: 22 nTPM
- gallbladder: 5.6 nTPM
Single-cell type
- colonocytes: 129 nCPM
- enterocytes: 98 nCPM
- enteric transient amplifying cells: 41 nCPM
- epicardial cells: 30 nCPM
- cardiomyocytes: 28 nCPM
- proximal tubule cells: 28 nCPM
Immune cell
- basophil: 0.2 nTPM
- naive B-cell: 0.2 nTPM
- classical monocyte: 0.1 nTPM
- memory CD4 T-cell: 0.1 nTPM
- neutrophil: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
Brain region
- choroid plexus: 4.1 nTPM
- cerebellum: 2.7 nTPM
- white matter: 2.7 nTPM
- midbrain: 2.5 nTPM
- hypothalamus: 2.4 nTPM
- medulla oblongata: 2.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.78
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.44
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- host-mediated modulation of intestinal microbiota composition
- positive regulation of canonical NF-kappaB signal transduction
- positive regulation of non-canonical NF-kappaB signal transduction
- regulation of cytokine production
- regulation of inflammatory response
- toll-like receptor signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Cysteine-rich flanking region, C-terminal
- Leucine-rich repeat
- Leucine-rich repeat, typical subtype
- Leucine-rich repeat domain superfamily
- Leucine rich repeat
- Leucine-rich repeat family 19 TM domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LRRC19 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LRRC19 as an antibody target. Whether an autoantibody or antibody against LRRC19 could matter depends on whether native LRRC19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LRRC19 is annotated at the cell surface, where native LRRC19 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LRRC19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...